01 / DESIGN
What was studied?
After an open-label tirzepatide lead-in, 670 participants were randomized either to continue treatment or to switch to placebo for a further 52 weeks.
02 / FINDINGS
What did the researchers report?
Continuing treatment maintained and extended the average initial weight reduction. Participants switched to placebo regained substantial weight. Gastrointestinal adverse events remained relevant.
03 / LIMITS
How should it be interpreted?
Randomization occurred after the lead-in, so these results describe people who reached that stage rather than everyone starting treatment. This design does not demonstrate that benefits persist indefinitely after withdrawal.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.